Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Magenta in-licenses Novartis' HSC835 UCB stem cell therapy candidate; later reveals $302mm PDV

Executive Summary

Concurrent with completing a GV-led $50mm Series B round, stem cell therapies start-up Magenta Therapeutics Inc. in-licensed Novartis AG's HSC835, an investigational intravenous therapy for enhancing umbilical cord blood (UCB) stem cells for transplant.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies